A real-world, multicentre, retrospective study of rFIXFc for patients with haemophilia B after switching to recombinant factor IX Fc fusion protein (rFIXFc) for up to 5 years
Latest Information Update: 27 Aug 2021
At a glance
- Drugs Eftrenonacog alfa (Primary)
- Indications Haemophilia B
- Focus Adverse reactions; Therapeutic Use
- 27 Aug 2021 New trial record